Skip to main content
NeuroWiki
Trial

Historical Reference Page

This is a historical reference page. This trial preceded the modern evidence base. It is presented as a predecessor reference. See ENRICH (2024) for the modern successor trial that established minimally invasive evacuation for selected lobar intracerebral hemorrhage.

MISTIE III Trial: Minimally Invasive Surgery Plus rt-PA for ICH Evacuation

In patients with supratentorial intracerebral hemorrhage of 30 mL or larger, does image-guided catheter placement plus intermittent alteplase improve 1-year functional outcome compared with standard medical management?

Hanley et al. (Lancet 2019) · doi:10.1016/S0140-6736(19)30195-3 · 506 patients

Population

Included

  • Supratentorial spontaneous ICH 30 mL or larger on baseline CT
  • Age 18 years or older
  • At least 12 hours post-ictus (clinical stability required)
  • Hematoma accessible for stereotactic catheter placement
  • GCS 5 or greater

Excluded

  • Infratentorial (posterior fossa) hemorrhage
  • ICH secondary to anticoagulation, AVM, aneurysm, or tumor
  • Planned early craniotomy within 24 hours
  • Intraventricular hemorrhage causing obstructive hydrocephalus requiring immediate intervention
  • INR above 1.5 or platelets below 100,000 at enrollment

Source: Hanley et al., Lancet 2019· Retrieved 2026-06-09

Primary Outcome — mRS 0-3 at 1 Year

506 patients; image-guided catheter + alteplase vs standard medical management; supratentorial ICH ≥30 mL

In 506 patients with supratentorial ICH 30 mL or larger randomized to image-guided catheter plus alteplase or standard medical management, MISTIE did not significantly improve functional independence (mRS 0-3) at 1 year. mRS 0-3 was achieved in 45% (110 of 245) in the MISTIE group versus 41% (103 of 250) in the standard care group (adjusted OR 1.20, 95% CI 0.81 to 1.81, P=0.33). A pre-specified subgroup analysis showed a significant benefit in patients achieving end-of-treatment hematoma volume 15 mL or less (OR approximately 1.79, 95% CI 1.03 to 3.12), suggesting that the degree of hematoma reduction, not just the technique, is the critical determinant of outcome.

OR (mRS 0-3 at 1 year)1.20
95% CI0.81 to 1.81
ResultNot significant (P=0.33)

Visualization not shown for predecessor reference pages. See source paper for figures.

Trial Design

MISTIE III was an international phase 3 RCT enrolling patients with supratentorial ICH 30 mL or larger who were at least 12 hours from ictus and clinically stable. A CT-guided stereotactic catheter was placed into the hematoma and alteplase (1 mg every 8 hours, up to 9 doses over approximately 72 hours) was instilled to lyse the clot; fluid was drained passively. The target was residual hematoma 15 mL or less before catheter removal. The 1-year follow-up was longer than most surgical ICH trials. MISTIE differed fundamentally from ENRICH in technique: catheter-based lysis versus trans-sulcal surgical aspiration, with the latter achieving faster and more complete evacuation.

Safety

Procedural symptomatic intracranial hemorrhage occurred in 5.8% of MISTIE patients during the treatment period versus 1.9% in the standard care group. Bacterial meningitis or ventriculitis occurred in 5.7% of MISTIE patients from prolonged catheter indwelling. There was no significant difference in overall 1-year mortality between groups.

NeuroWiki is a clinical reference. It does not substitute for your clinical judgment, current guidelines, or your institution's protocol. Verify before acting. Do not enter patient names, MRNs, or dates of birth. Privacy Policy